Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:acquisitionYear |
2017
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
oncology
|
| gptkbp:founded |
1991
|
| gptkbp:founder |
gptkb:Harvey_J._Berger
|
| gptkbp:headquarters_location |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ariad Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:keyPerson |
gptkb:Harvey_J._Berger
gptkb:Paris_Panayiotopoulos gptkb:Timothy_P._Clackson |
| gptkbp:market |
gptkb:Europe
gptkb:United_States |
| gptkbp:notableEvent |
FDA approval of Iclusig (ponatinib) in 2012
|
| gptkbp:notableProduct |
gptkb:brigatinib
gptkb:ponatinib |
| gptkbp:numberOfEmployees |
~300 (before acquisition)
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:researchArea |
targeted cancer therapies
|
| gptkbp:status |
defunct
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:ARIA
|
| gptkbp:website |
www.ariad.com
|
| gptkbp:bfsParent |
gptkb:brigatinib
|
| gptkbp:bfsLayer |
6
|